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In 2010, a tissue-engineered trachea was transplanted
into a 10-year-old child using a decellularized deceased
donor trachea repopulated with the recipient’s respira-
tory epithelium and mesenchymal stromal cells. We
report the child’s clinical progress, tracheal epitheliali-
zationandcostsover the4years.Achronologyofevents
was derived from clinical notes and costs determined
using reference costs per procedure. Serial tracheo-
scopy images, lung function tests and anti-HLA blood
samples were compared. Epithelial morphology and T
cell, Ki67 and cleaved caspase 3 activitywere examined.
Computational fluid dynamic simulations determined
flow, velocity and airway pressure drops. After the first
year following transplantation, the number of inter-
ventions fell and the child is currently clinicallywell and
continues in education. Endoscopy demonstrated a
complete mucosal lining at 15 months, despite reten-
tion of a stent. Histocytology indicates a differentiated
respiratory layer and no abnormal immune activity.
Computational fluid dynamic analysis demonstrated
increased velocity and pressure drops around a distal
tracheal narrowing. Cross-sectional area analysis
showed restriction of growth within an area of in-stent
stenosis. This report demonstrates the long-term
viability of a decellularized tissue-engineered trachea
within a child. Further research is needed to develop
bioengineered pediatric tracheal replacements with
lower morbidity, better biomechanics and lower costs.
Abbreviations: GMP, good manufacturing practice;
GOSH, Great Ormond Street Hospital; ICU, intensive
care unit
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Introduction
The application of tissue engineering to restore a segment
of airway in those with long-segment tracheal stenosis
resistant to treatment is now realistic. Such therapies
remain highly controversial, however, due to uncertainty
regarding long-term benefit, quality of life and comparative
cost. A 5-year follow-up of the first tissue-engineered
airway in an adult reported normal lung function and a good
quality of life long-term albeit with the need for serial
insertions of airway stents (1,2). Approaches based on
synthetic scaffolds have also been reported, though only
with short-term follow-up to date (3).
In 2012, we reported a 2-year follow-up of the first tissue-
engineered tracheal transplant in a child using a decellular-
ized deceased donor trachea repopulatedwith the patient’s
own respiratory epithelial cells and mesenchymal stromal
cells (4). While this demonstrated the validity of this
approach in reconstructing an airway over a 2-year period, a
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number of key questions remain unanswered. The trachea
continues to grow up to adulthood and it is still not known
whether a transplanted engineered airway has capacity for
growth (5). The long-term outcome is also unclear in terms
of how the graft remodels over time, whether it continues
to support regenerated epithelium and if it continues to be
unchallenged by the immune system. An evaluation of the
quality of life of the recipient, a chronology of events and
estimation of cost is necessary to evaluate the potential for
a wider application of this technology and its place within a
healthcare system. We address these questions by
reporting observations of this child’s clinical progress and
tracheal epithelialization 4 years after implantation.
Materials and Methods
Clinical datawere collated from the patient notes documenting his long-term
care at Great Ormond Street Hospital (GOSH). The Peds QL parent-proxy
assessment tool was used as a validatedmethod of analyzing health-related
quality of life in children with chronic disease and associated learning
disabilities (6).
Neck and chest computed tomography scans at 3 months (June 2010),
42 months (September 2013) and 49 months (April 2014) following
transplantation were compared. 3D reconstructions of the tracheal lumen
were performed using Mimics
1
Innovation Suite (Materialise, Materialise
Belgium – Technologielaan 15, Leuven, Belgium). Cross-sectional area of the
trachea was calculated followingmethods previously described (7). Tracheal
airflowwas calculated using a validatedmethod through computational fluid
dynamics (8,9).
Endoscopy images of the transplanted trachea were obtained during
microlaryngobronchoscopy performed at 15 days, 6, 15 and 42 months
following transplantation using a 15-mm zero degree Hopkins Rod and
image capture (Karl Storz, Tuttlingen, Germany).
Biopsysampleswere routinelyprocessedfollowing formalinfixation, followed
by paraffin wax embedding and cutting of 4-mm sections onto glass slides for
hematoxylin and eosin (H&E) staining and immunostaining using an
automated immunostainer (Leica Bond-Max, Leica, Wetzlar, Germany).
Samples of cilia were obtained during routine flexible bronchoscopy by
brushing the trachea with a 2-mm cytology brush (Olympus Endotherapy,
Olympus, Skinjuku-ku, Tokyo) (10). Samples were analyzed using a digital
high-speed video camera (MotionPro X4, IDT, CA) at a frame rate of 500
frames s–1 to allow assessment of ciliary beat frequency and pattern.
The costing for the clinical items were obtained using a combination of NHS
reference costs (2010–2011 period) per procedure appropriate for a male
child and typical costs for complex tracheal patients provided by GOSH. The
laboratory costs were estimated from data gathered from the good
manufacturing practice (GMP) laboratories where further grafts were
constructed to treat two later patients (data not shown).
Results
Chronology of events
Following transplantation at GOSH inMarch 2010, the child
returned to the intensive care unit (ICU; unit providing level
2 and 3 care) where he remained an inpatient for 8 days,
before being discharged from critical care (11). He required
25 procedures postoperatively, mainly to clear secretions
and granulation tissue (Figure 1). The graft itself was
malacic in the initial period necessitating the insertion of
two bioabsorbable tracheal stents. On four occasions
during the initial period admission to the ICU was needed
for respiratory support.
The child was discharged home in August 2010, but
required a number of return visits to GOSH to address
retained secretions, granulation and a malacic segment in
the distal transplanted trachea, necessitating the insertion
of further stents, one bioabsorbable and two self-expanding
nitinol. There were two further admissions to ICU during
the first year follow up period and one ICU admission during
the second year follow up period.
Figure 1: Number of clinical events from transplantation to the fourth year of follow-up. The frequency of interventions fell
significantly following the first year after transplantation. B&B, bronchoscopy and bronchogram; CICU, cardiac intensive care unit; MLB,
microlaryngoscopy and bronchoscopy.
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By 6months, the airwaywas sufficiently stable to allow the
child to return to school and the need for repeated
interventions declined up to late 2013 when an infection
and stenosis within the tracheal stents and un-transplanted
left main bronchus necessitated intervention. Following
balloon dilatation of the trachea and left main bronchus,
the child made a good recovery and has now returned to
full-time education.
A Peds QL 4  0 parent proxy quality of life assessment was
completed in May 2014. Scores were 50, 60, 55 and 35 for
physical, emotional, social and school subscales, respec-
tively, with a total score of 50 out of 100. Since
transplantation, the child has grown 15 cm in height to
168 cm and gained 21 kg in weight to 58 kg.
Assessment of the transplanted trachea
Figure 2 shows the cross-sectional area comparison
derived from the 2010, 2013 and 2014 CT scans.
Comparison of the 2010 tracheal geometry to a normal
trachea demonstrates the formation of high velocity region
in its distal segment (Figure 3A) (12). In 2013, the velocity in
this region increased further and formed a jet 40mm below
the glottis. By 2014, the jet formed more proximally (circa
17mm subglottically). The effect of these changes in flow
pattern is seen in Figure 3B. Lung Function Tests in
October 2013 and April 2014 showed flattening of both
inspiratory and expiratory parts of the inspiratory/expiratory
flow volume curves consistent with a fixed obstruction of
the trachea.
Microlaryngoscopy 15 days after transplantation showed a
dense web covering the stent and partially occluding the
lumen (Figure 4A). At 42 months, a completemucosal layer
is demonstrated throughout the trachea (Figure 4B) with
the stents embedded beneath (Figure 5).
A section of the excised homograft trachea exhibited
normal ciliated respiratory type epithelium (Figure 6A). A
biopsy of the transplanted trachea 1-month following the
procedure showed granulation tissue only (Figure 6B). At
Figure 2: Cross-sectional variation in area along the length of
the trachea as derived from each scan. Both the more recent
measurements demonstrate growth at either end of the
transplanted section, whereas the 2010 measurements are more
constant along the length. The minimum area has reduced by
20.5% between 2010 and 2014, while the area has more than
doubled at the extremities. Below the area plot you can see a
reconstruction of the 2013 geometry and stent with the centerline
highlighted.
Figure 3: (A) Flow velocities. The velocity in the 2010 geometry is relatively uniform, similar to that of a healthy/normal individual in the
upper region, while somewhat accelerated in the lower part. By 2013, a constriction is apparent which leads to the formation of a jet in that
area. A longer constriction is seen in 2014 geometry which causes higher velocities in the upper region and a stronger jet below
necessitating intervention with balloon dilatation. (B) Relative pressure. Here, we see relative pressure plotted along the distance of the
centerline. 2013 showsan abrupt drop in pressure at the location of the jet,which then plateaus, to a pressure drop slightly higher than that in
2010. The long constriction and strong jet in 2014 results in double the pressure drop when compared to the 2010 geometry.
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42 months, a biopsy of the proximal transplant showed a
complete epithelial layer with a mix of squamoid and
respiratory type epithelium with scanty ciliated cells
(Figure 6C). An immunostained section using CD3 demon-
strated no evidence of rejection or lymphocyte-associated
epithelial damage and normal submucosal T cell density
(Figure 6D). Staining for Ki67 was normal and cleaved
caspase 3 was negative in both pre and posttransplant
specimens. Serial serological examination to date has
shown no evidence of anti-donor HLA antibodies.
Brushings on routine endoscopy in April 2014 demonst-
rated ciliated epithelial cells. Ciliary beat frequency was
within the normal range at 10.7Hz (95% confidence
Figure 4: Bronchoscopy appearances. (A)Microlaryngoscopy 15 days after transplantation demonstrates a denseweb and inflammation
within the transplanted segment partially occluding the airway. (B) At 42months after surgery a completemucosal layer can be seenwithin
the transplanted segment and a widely patent airway is seen.
Figure 5: Computer tomography images: axial, coronal, and sagittal sections taken in 2010 and 2013. The stents can be seen
embedded within the tracheal wall in the 2013 scans (*). The narrowed transplanted segment is visible in both the 2010 and 2013 images.
The left sided superior vena cava is not unusual in patients with long segment congenital tracheal stenosis.
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intervals 10  4–11  0) with a normal ciliary beat pattern. On
electron microscopy, structurally normal ciliary axonemes
were observed.
Cost of treatment
The total clinical cost of the transplant and follow-up care to
March 2014 was calculated to be US$565414 (£/$
exchange rate 1:1.56) (Table 1). The costs for treatment
from the date of transplant up to first discharge fromGOSH
contributed to 76% of the total clinical cost, at US$427255.
Following discharge, the clinical costs were less at US
$94749, US$20 693, under US$1560 and US$21 835 for
the first, second, third and fourth years, respectively
(Figure 7). The laboratory costs of preparing the tissue-
engineered trachea were estimated to be US$15600.
Discussion
The use of a tissue-engineered tracheal transplant is
currently a potential treatment of last resort. In the reported
case, all conventional therapies had failed and the
technique was used on compassionate grounds in an
urgent setting. This intervention has not only preserved life
for more than 4 years, but has enabled the child to mature,
continue education and be free of medical intervention for
long periods. Indeed, the timing and frequency of
interventions between the 1st and 4th years following
transplantation compare favorably to children suffering
Figure 6: Photomicrographs demonstrating (A) resected homograft trachea March 2010, (B) biopsy of tissue engineered tracheal lining 1
month after transplantation showing extensive granulation tissue, (C) biopsy of proximal tissue-engineered trachea at 42 months showing
complete re-epithelialization and with scanty ciliated cells, (D) CD3 immunostain for T-lymphocytes on tracheal biopsy (42 months)
demonstrating normal submucosal T cell density.
Table 1: Interventions and corresponding costings for first period,
i.e., first admission to first official discharge
Cost ($ approximately)
Ward and ICU stays $157 265
Imaging $333
Broncoscopies $1939
Surgery costs1 $268 881
Total $428 418
ICU, intensive care unit; MLB, microlaryngoscopy and bronchoscopy.
1IncludingMLBs, stent insertion and removal, bonemarrowaspiration
for cell harvest, and the procedures involved in the graft transplant
itself.
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from recurrent tracheal stenosis or those with metallic
tracheal stents treated in our institution.
The Peds QL score is consistent with a child suffering
from a complex chronic disease (13). A low physical
subscale mainly accounted for this and his co-existing
conditions, including spastic diplegia, make it difficult to
determine the contribution of his airway disease alone to
this score.
The emergent nature of our case necessitated the use of
intraoperative native airway epithelial patches to re-
epithelialize the graft (4). The absence of a safe and
effective method of monitoring epithelial fate in vivo in
humans prohibits observations of the fate of such
epithelium. A number of preclinical studies have indicated
re-epithelialization occurs from migration of cells from the
wound edge following tracheal transplantation (14,15),
tracheal replacement with aortic grafts (16,17) or synthetic
material (18). While this might question the need for re-
epithelizing grafts prior to transplantation, evidence exists
supporting the role of epithelium in reducing postoperative
stenosis and it is probable that transplanted epithelia act as
a biological dressing as re-epithelization occurs from the
wound edge (19).
Alternative protocols for epithelizing tracheal grafts use
cadaveric tracheal cartilage prevascularized within radial
forearm fascia and lined with autologous buccal muco-
sa (20,21).While this approach has reported some success,
it is limited by the need for prolonged periods of
immunosuppression and the delivery of squamous rather
than ciliated epithelium within the airway. The emergent
circumstances of our case meant this approach was
unsuitable as there was insufficient time for prevascular-
isation. It is hoped with advances in cell expansion
techniques and biomaterials that it will be possible to
deliver a fully differentiated autologous respiratory epithelial
sheet as has been reported with buccal and corneal
epithelium (22,23). This, in combination with a prevascu-
larised decellularized tracheal scaffold, would allow for the
delivery of a vascularized epithelized tracheal graft without
immunosuppression.
A cross-sectional centerline analysis suggested growth at
the proximal and distal portions of the trachea over time.
Cross-sectional area is restricted at 15–45mm below the
first tracheal ring in all scans corresponding to an area of in-
stent stenosis. It is not possible to determine whether the
transplanted trachea would have grown had in-stent
stenosis been avoided. Whether the transplanted section
includes viable tracheal cartilage can also not be deter-
mined with routine investigations. However, a complete
mucosal layer, dynamic movement of the airway and
demonstrable tracheal rings on endoscopy indicate the
transplanted trachea is functioning as a cartilaginous frame.
Of note, recurrent stenosis has been reported in the other
example of a decellularized airway transplant (1).
We also report, for the first time to our knowledge, the use
of computational fluid dynamic simulations within a
reconstructed trachea. This validated technique provides
detailed information on how distinct geometrical features
correlate with airflow distribution and provides information
Figure 7: Chart showing the cost of clinical treatment within the initial postoperative period to the fourth year of follow-up. Clinical costs fell
significantly after the initial admission and further still after the first year. Costs slightly increased in the fourth year due to an illness requiring
dilatation of an old left bronchial stent.
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on pressure (7,8,12). Our results demonstrate an increasing
pressure drop at the distal segment of the transplanted
trachea due to the jet shown in Figure 3 and highlighted the
area most in need of intervention with a corresponding
improvement in symptomatology following targeted treat-
ment. We hypothesize that similar results can be derived
from high-field-strengthmagnetic resonance imaging using
these techniques to provide accurate, personalized and
noninvasive planning, and follow-up following large airway
surgery, including transplantation.
The total cost of this tissue-engineered tracheal transplant
is greater than conventional forms of airway management;
however, our approach is only indicated for a small subset
of children with airway stenosis and the calculated costs
herein are unlikely to be prohibitive within a modern
healthcare system. Our observations and interpretations of
the problems the child faced in this early period have fed
back into substantially improved tissue-engineering proto-
cols, and an advanced GMP process which will lead to
substantial, iterative, reductions in hospital stay, complica-
tions and, thus, costs.
To our knowledge, this is the first long-term follow-up
report of a child receiving a tissue-engineered trachea.
Further research is required to develop bioengineered
pediatric tracheal replacements with lower morbidity,
better biomechanics and at a cost acceptable to healthcare
providers. Future clinical trials of such constructs should
include comprehensive assessments of airway physiology,
biology, quality of life, and health economics.
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